Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.30 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17721726 | 0.80 | GLP1R (0.33) | GLP1R | |
| SCHEMBL22930834 | 0.79 | MBOAT4 (0.34) | GLP1R | |
| SCHEMBL22964601 | 0.78 | ABL1 (0.37) | KDM4ESMN1; SMN2ALDH1A1RPS6KA5 | |
| SCHEMBL16248184 | 0.78 | S100A9 (0.33) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL12413632 | 0.78 | SMN1; SMN2 (0.42) | KDM4ESMN1; SMN2ALDH1A1RPS6KA5 | |
| SCHEMBL20049808 | 0.78 | P2RX3 (0.40) | — | |
| SCHEMBL1428249 | 0.70 | KDM4E (0.34) | KDM4ESMN1; SMN2ALDH1A1CSNK1A1CLK4 | |
| SCHEMBL27223922 | 0.69 | NFKB1 (0.39) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL1188746 | 0.69 | — | — | |
| SCHEMBL14556309 | 0.68 | ATM (0.36) | KDM4ESMN1; SMN2ALDH1A1RPS6KA5RPS6KA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112055711-B | Cyclohexylic acid triazolazine as LPA antagonist | 百时美施贵宝公司 | 2024-07-23 | — | — | CN | disclosed |
| EP-3728223-B1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-3728223-B1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-12-28 | — | — | EP | disclosed |
| US-11267800-B2 | Cyclohexyl acid triazole azines as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-03-08 | — | — | US | disclosed |
| US-20210230143-A1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210230143-A1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-29 | — | — | US | disclosed |
| EP-3728223-A1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2020-10-28 | — | — | EP | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267800-B2 | Cyclohexyl acid triazole azines as LPA antagonists | LPAR3, LPAR1, LPAR2 | GLP1R 94/4885KDM4E 3399/4885SMN1; SMN2 4323/4885 |
| US-20210230143-A1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | GLP1R 94/4885KDM4E 3399/4885SMN1; SMN2 4323/4885 |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | GLP1R 29/4885KDM4E 3718/4885SMN1; SMN2 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.